Sermorelin Acetate, also known as GRF 1-29 Amide, is a Growth Hormone Releasing Hormone (GHRH) produced by the brain that stimulates the production and release of Growth Hormone (GH). Sermorelin Acetate was first developed in the 70s, which is thought to be the shortest fully functional fragment of GHRH and has been used as a test for Growth Hormone secretion. Sermorelin Acetate affects a more primary source of failure in the GH neuroendocrine axis, has more physiological activity, and its use for hormone deficiency is not restricted. Compared to Growth Hormone (HGH), Sermorelin Acetate is a growth hormone secretagogue, which means that it stimulates the pituitary gland to produce and secrete growth hormone. Also, Sermorelin Acetate and Modified GRF 1-29 contain 29 amino acids whereas hGH is a larger molecule containing 191 amino acids.
What is Sermorelin?
Sermorelin is a GHRH (growth hormone–releasing hormone) peptide analogue. Its peptide sequence is comprised of 29 amino acids. This sequence is a portion of the endogenous human GHRH and is currently considered to be the shortest synthetic peptide that possesses the full array of functional GHRH activity. Due to this fact, sermorelin is considered to be a growth hormone secretagogue.
Sermorelin has been used during research to stimulate the secretion of growth hormone from the adenohypophysis (also called the anterior pituitary). The anterior pituitary secretes trophic hormones. Sermorelin has also been used in research stimulation tests to assess for pituitary sufficiency in relation to the secretion of the growth hormone.
Sermorelin Acetate, which shares a similar structure to CJC-1295, is a bio-identical synthetic hormone that is extremely effective in increasing the amount of HGH. Growth Hormone is a hormone released by the body that controls the reproduction and growth of the cells and each of the organs in the body. At a young age, the body’s GH production is most active while the growth rate is at its highest point. After the age of 30, for every decade of life, there is a 14% reduction in GH production. By the age of 40, GH production is about 40 percent of what it was at the age of 20. With further development in a research environment, growth hormone releasing factors (GHRF), such as Modified GRF 1-29, GH production may begin again by stimulating the pituitary gland.
Since 1980, scientists have been studying GHRH for many years. Dr. D. Rudman was testing Sermorelin as a tool for anti-aging processes, and Dr. William Wehrenberg was looking at different peptides and particularly GHRH to identify which part of it is needed for pituitary gland stimulating a response. His results after eliminating single amino acids showed that 29-acid-chains were held responsible for pituitary stimulation. Many research studies have concluded that Sermorelin is a well-tolerated analogue of GHRH. As a result, this is suitable for use as a provocative test of growth hormone deficiency (Prakash and Goa 1999). In 1999, both researchers, Goa and Prakash checked Sermorelin Growth Hormone as a provocative method for deficiency of endogenous G-hormone. Sermorelin therapy increased the volume of hormone secreted by the stimulated pituitary gland, which is later converted by the liver into IGF-1. The increased amount of IGF-1 in the bloodstream leads to many benefits from the use of Sermorelin: increasing metabolism and growth of new cells within the body’s organs and bones.
1.Esposito P, Barbero L, Caccia P, Caliceti P, D’Antonio M, Piquet G, Veronese FM: PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1279-91. [PubMed:14499707]
2.Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Information is for educational/research purposes only.